International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy
- PMID: 37702631
- DOI: 10.1016/j.jtho.2023.07.017
International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy
Abstract
Introduction: Pathologic response has been proposed as an early clinical trial end point of survival after neoadjuvant treatment in clinical trials of NSCLC. The International Association for the Study of Lung Cancer (IASLC) published recommendations for pathologic evaluation of resected lung cancers after neoadjuvant therapy. The aim of this study was to assess pathologic response interobserver reproducibility using IASLC criteria.
Methods: An international panel of 11 pulmonary pathologists reviewed hematoxylin and eosin-stained slides from the lung tumors of resected NSCLC from 84 patients who received neoadjuvant immune checkpoint inhibitors in six clinical trials. Pathologic response was assessed for percent viable tumor, necrosis, and stroma. For each slide, tumor bed area was measured microscopically, and pre-embedded formulas calculated unweighted and weighted major pathologic response (MPR) averages to reflect variable tumor bed proportion.
Results: Unanimous agreement among pathologists for MPR was observed in 68 patients (81%), and inter-rater agreement (IRA) was 0.84 (95% confidence interval [CI]: 0.76-0.92) and 0.86 (95% CI: 0.79-0.93) for unweighted and weighted averages, respectively. Overall, unweighted and weighted methods did not reveal significant differences in the classification of MPR. The highest concordance by both methods was observed for cases with more than 95% viable tumor (IRA = 0.98, 95% CI: 0.96-1) and 0% viable tumor (IRA = 0.94, 95% CI: 0.89-0.98). The most common reasons for discrepancies included interpretations of tumor bed, presence of prominent stromal inflammation, distinction between reactive and neoplastic pneumocytes, and assessment of invasive mucinous adenocarcinoma.
Conclusions: Our study revealed excellent reliability in cases with no residual viable tumor and good reliability for MPR with the IASLC recommended less than or equal to 10% cutoff for viable tumor after neoadjuvant therapy.
Keywords: Lung cancer; MPR; Neoadjuvant therapy; Reproducibility.
Copyright © 2023. Published by Elsevier Inc.
Similar articles
-
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).Ann Oncol. 2018 Aug 1;29(8):1853-1860. doi: 10.1093/annonc/mdy218. Ann Oncol. 2018. PMID: 29982279 Free PMC article. Clinical Trial.
-
Histological Assessment and Interobserver Agreement in Major Pathologic Response for Non-Small Cell Lung Cancer with Neoadjuvant Therapy.Cancer Res Treat. 2024 Sep 9. doi: 10.4143/crt.2024.670. Online ahead of print. Cancer Res Treat. 2024. PMID: 39265620
-
Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study.J Thorac Oncol. 2024 May;19(5):719-731. doi: 10.1016/j.jtho.2023.12.010. Epub 2023 Dec 7. J Thorac Oncol. 2024. PMID: 38070597
-
Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice.JTO Clin Res Rep. 2022 Mar 19;3(5):100310. doi: 10.1016/j.jtocrr.2022.100310. eCollection 2022 May. JTO Clin Res Rep. 2022. PMID: 35498382 Free PMC article. Review.
-
Pathologic Response Evaluation in Neoadjuvant-Treated Lung Cancer.Surg Pathol Clin. 2024 Jun;17(2):287-293. doi: 10.1016/j.path.2023.11.010. Epub 2023 Dec 21. Surg Pathol Clin. 2024. PMID: 38692811 Review.
Cited by
-
Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology.Sci Rep. 2024 Oct 15;14(1):24163. doi: 10.1038/s41598-024-75175-w. Sci Rep. 2024. PMID: 39406837 Free PMC article.
-
Whole slide image-based weakly supervised deep learning for predicting major pathological response in non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a multicenter, retrospective, cohort study.Front Immunol. 2024 Sep 20;15:1453232. doi: 10.3389/fimmu.2024.1453232. eCollection 2024. Front Immunol. 2024. PMID: 39372403 Free PMC article.
-
Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy.Adv Anat Pathol. 2024 Sep 1;31(5):324-332. doi: 10.1097/PAP.0000000000000441. Epub 2024 Apr 9. Adv Anat Pathol. 2024. PMID: 38595110 Free PMC article. Review.
-
Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective.Lancet Reg Health Eur. 2024 Mar 1;38:100841. doi: 10.1016/j.lanepe.2024.100841. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38476749 Free PMC article. Review.
-
Pathological response and tumor stroma immunogenic features predict long-term survival in non-small cell lung cancer after neoadjuvant chemotherapy.Cell Oncol (Dordr). 2024 Jun;47(3):1005-1024. doi: 10.1007/s13402-023-00914-6. Epub 2024 Feb 6. Cell Oncol (Dordr). 2024. PMID: 38319500
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical